A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are bein...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of Cancer Research and Therapy 2016/01/13, Vol.24(1), pp.17-22
Hauptverfasser: Ishibashi, Keiichiro, Kumamoto, Kensuke, Koda, Keiji, Kato, Hiroyuki, Nishimura, Genichi, Yoshimatsu, Kazuhiko, Yokomizo, Hajime, Ooki, Shinji, Tanaka, Soichi, Asano, Michio, Yokoyama, Masaru, Kawada, Tomoyuki, Ishida, Hideyuki
Format: Artikel
Sprache:eng
Schlagworte:
adjuvant chemotherapy
colon cancer
oxaliplatin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 22
container_issue 1
container_start_page 17
container_title Annals of Cancer Research and Therapy
container_volume 24
creator Ishibashi, Keiichiro
Kumamoto, Kensuke
Koda, Keiji
Kato, Hiroyuki
Nishimura, Genichi
Yoshimatsu, Kazuhiko
Yokomizo, Hajime
Ooki, Shinji
Tanaka, Soichi
Asano, Michio
Yokoyama, Masaru
Kawada, Tomoyuki
Ishida, Hideyuki
description This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.
doi_str_mv 10.4993/acrt.24.17
format Article
fullrecord <record><control><sourceid>jstage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_4993_acrt_24_17</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>article_acrt_24_1_24_17_22_article_char_en</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4307-df51ced3469946709e4f19be11a56afd7b3d9bafbe95551e3920adb4673869ba3</originalsourceid><addsrcrecordid>eNpFkN1Kw0AQhYMoWKs3PsFeC2mz2c3PemUIRguBiK3QuzDZTExKmpTdbaGP4FubEKlXM8z5OIczlvVInQUXgi1BKrNw-YIGV9aMhqFje9wX18POOLf9kHm31p3WO8fhvue7M-snIh81aCSrFYnbpmsktGRtjuWZ9BXZJ1maZFufLLevabYloElU7o4n6AyJa9z3pkYFhzOByqAi8VGBaU5IPlGjNE3fjSZrA9-j_xDQt8Mphk6ieiabGkkSxdl6yru3bipoNT78zbn1lbxu4nc7zd5WcZTakjMnsMvKoxJLNtQS3A8cgbyiokBKwfOhKoOClaKAqkDheR5FJlwHymJAWegPAptbT5OvVL3WCqv8oJo9qHNOnXx8Yj4-MXd5ToMBfpngnR5bXFBQppEt_qMTn7vuRZI1qBw79gu-HXuM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study</title><source>J-STAGE Free</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ishibashi, Keiichiro ; Kumamoto, Kensuke ; Koda, Keiji ; Kato, Hiroyuki ; Nishimura, Genichi ; Yoshimatsu, Kazuhiko ; Yokomizo, Hajime ; Ooki, Shinji ; Tanaka, Soichi ; Asano, Michio ; Yokoyama, Masaru ; Kawada, Tomoyuki ; Ishida, Hideyuki</creator><creatorcontrib>Ishibashi, Keiichiro ; Kumamoto, Kensuke ; Koda, Keiji ; Kato, Hiroyuki ; Nishimura, Genichi ; Yoshimatsu, Kazuhiko ; Yokomizo, Hajime ; Ooki, Shinji ; Tanaka, Soichi ; Asano, Michio ; Yokoyama, Masaru ; Kawada, Tomoyuki ; Ishida, Hideyuki</creatorcontrib><description>This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.</description><identifier>ISSN: 1344-6835</identifier><identifier>EISSN: 1880-5469</identifier><identifier>DOI: 10.4993/acrt.24.17</identifier><language>eng</language><publisher>The Japanese Society of Strategies for Cancer Research and Therapy</publisher><subject>adjuvant chemotherapy ; colon cancer ; oxaliplatin</subject><ispartof>Annals of Cancer Research and Therapy, 2016/01/13, Vol.24(1), pp.17-22</ispartof><rights>2016 by The Japanese Society of Strategies for Cancer Research and Therapy</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4307-df51ced3469946709e4f19be11a56afd7b3d9bafbe95551e3920adb4673869ba3</citedby><cites>FETCH-LOGICAL-c4307-df51ced3469946709e4f19be11a56afd7b3d9bafbe95551e3920adb4673869ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,4010,27900,27901,27902</link.rule.ids></links><search><creatorcontrib>Ishibashi, Keiichiro</creatorcontrib><creatorcontrib>Kumamoto, Kensuke</creatorcontrib><creatorcontrib>Koda, Keiji</creatorcontrib><creatorcontrib>Kato, Hiroyuki</creatorcontrib><creatorcontrib>Nishimura, Genichi</creatorcontrib><creatorcontrib>Yoshimatsu, Kazuhiko</creatorcontrib><creatorcontrib>Yokomizo, Hajime</creatorcontrib><creatorcontrib>Ooki, Shinji</creatorcontrib><creatorcontrib>Tanaka, Soichi</creatorcontrib><creatorcontrib>Asano, Michio</creatorcontrib><creatorcontrib>Yokoyama, Masaru</creatorcontrib><creatorcontrib>Kawada, Tomoyuki</creatorcontrib><creatorcontrib>Ishida, Hideyuki</creatorcontrib><title>A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study</title><title>Annals of Cancer Research and Therapy</title><addtitle>Ann. Cancer Res. Therap.</addtitle><description>This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.</description><subject>adjuvant chemotherapy</subject><subject>colon cancer</subject><subject>oxaliplatin</subject><issn>1344-6835</issn><issn>1880-5469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpFkN1Kw0AQhYMoWKs3PsFeC2mz2c3PemUIRguBiK3QuzDZTExKmpTdbaGP4FubEKlXM8z5OIczlvVInQUXgi1BKrNw-YIGV9aMhqFje9wX18POOLf9kHm31p3WO8fhvue7M-snIh81aCSrFYnbpmsktGRtjuWZ9BXZJ1maZFufLLevabYloElU7o4n6AyJa9z3pkYFhzOByqAi8VGBaU5IPlGjNE3fjSZrA9-j_xDQt8Mphk6ieiabGkkSxdl6yru3bipoNT78zbn1lbxu4nc7zd5WcZTakjMnsMvKoxJLNtQS3A8cgbyiokBKwfOhKoOClaKAqkDheR5FJlwHymJAWegPAptbT5OvVL3WCqv8oJo9qHNOnXx8Yj4-MXd5ToMBfpngnR5bXFBQppEt_qMTn7vuRZI1qBw79gu-HXuM</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>Ishibashi, Keiichiro</creator><creator>Kumamoto, Kensuke</creator><creator>Koda, Keiji</creator><creator>Kato, Hiroyuki</creator><creator>Nishimura, Genichi</creator><creator>Yoshimatsu, Kazuhiko</creator><creator>Yokomizo, Hajime</creator><creator>Ooki, Shinji</creator><creator>Tanaka, Soichi</creator><creator>Asano, Michio</creator><creator>Yokoyama, Masaru</creator><creator>Kawada, Tomoyuki</creator><creator>Ishida, Hideyuki</creator><general>The Japanese Society of Strategies for Cancer Research and Therapy</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2016</creationdate><title>A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study</title><author>Ishibashi, Keiichiro ; Kumamoto, Kensuke ; Koda, Keiji ; Kato, Hiroyuki ; Nishimura, Genichi ; Yoshimatsu, Kazuhiko ; Yokomizo, Hajime ; Ooki, Shinji ; Tanaka, Soichi ; Asano, Michio ; Yokoyama, Masaru ; Kawada, Tomoyuki ; Ishida, Hideyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4307-df51ced3469946709e4f19be11a56afd7b3d9bafbe95551e3920adb4673869ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>adjuvant chemotherapy</topic><topic>colon cancer</topic><topic>oxaliplatin</topic><toplevel>online_resources</toplevel><creatorcontrib>Ishibashi, Keiichiro</creatorcontrib><creatorcontrib>Kumamoto, Kensuke</creatorcontrib><creatorcontrib>Koda, Keiji</creatorcontrib><creatorcontrib>Kato, Hiroyuki</creatorcontrib><creatorcontrib>Nishimura, Genichi</creatorcontrib><creatorcontrib>Yoshimatsu, Kazuhiko</creatorcontrib><creatorcontrib>Yokomizo, Hajime</creatorcontrib><creatorcontrib>Ooki, Shinji</creatorcontrib><creatorcontrib>Tanaka, Soichi</creatorcontrib><creatorcontrib>Asano, Michio</creatorcontrib><creatorcontrib>Yokoyama, Masaru</creatorcontrib><creatorcontrib>Kawada, Tomoyuki</creatorcontrib><creatorcontrib>Ishida, Hideyuki</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of Cancer Research and Therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishibashi, Keiichiro</au><au>Kumamoto, Kensuke</au><au>Koda, Keiji</au><au>Kato, Hiroyuki</au><au>Nishimura, Genichi</au><au>Yoshimatsu, Kazuhiko</au><au>Yokomizo, Hajime</au><au>Ooki, Shinji</au><au>Tanaka, Soichi</au><au>Asano, Michio</au><au>Yokoyama, Masaru</au><au>Kawada, Tomoyuki</au><au>Ishida, Hideyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study</atitle><jtitle>Annals of Cancer Research and Therapy</jtitle><addtitle>Ann. Cancer Res. Therap.</addtitle><date>2016</date><risdate>2016</risdate><volume>24</volume><issue>1</issue><spage>17</spage><epage>22</epage><pages>17-22</pages><issn>1344-6835</issn><eissn>1880-5469</eissn><abstract>This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.</abstract><pub>The Japanese Society of Strategies for Cancer Research and Therapy</pub><doi>10.4993/acrt.24.17</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1344-6835
ispartof Annals of Cancer Research and Therapy, 2016/01/13, Vol.24(1), pp.17-22
issn 1344-6835
1880-5469
language eng
recordid cdi_crossref_primary_10_4993_acrt_24_17
source J-STAGE Free; EZB-FREE-00999 freely available EZB journals
subjects adjuvant chemotherapy
colon cancer
oxaliplatin
title A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T16%3A27%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%20II%20Clinical%20Study%20of%20mFOLFOX6%20/XELOX%20as%20Adjuvant%20Chemotherapy%20after%20Curative%20Resection%20of%20Stage%20III%20Colon%20Cancer:%20The%20FACOS%20Study&rft.jtitle=Annals%20of%20Cancer%20Research%20and%20Therapy&rft.au=Ishibashi,%20Keiichiro&rft.date=2016&rft.volume=24&rft.issue=1&rft.spage=17&rft.epage=22&rft.pages=17-22&rft.issn=1344-6835&rft.eissn=1880-5469&rft_id=info:doi/10.4993/acrt.24.17&rft_dat=%3Cjstage_cross%3Earticle_acrt_24_1_24_17_22_article_char_en%3C/jstage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true